And so we’re almost half of that price. So we’re always going to be lower in price and try to be more accessible and more affordable. There are other intravitreal steroid products that are certainly over $1,400, $1,500 per unit. And so we remain significantly lower than them, but we did adjust the price to create enough profit incentive for us to invest in the product and make sure that we have a steady supply of the product to provide to the market, which is considerable.
Jeffrey Cohen: Awesome, thank you guys. Thanks again for the comprehensive comments here and read out. Appreciate it.
Mark L. Baum: Thank you Jeff.
Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Mark L. Baum, for any closing remarks.
Mark L. Baum: Thank you, Drew. And I guess I kind of want to apologize to those of you who are waiting for the issuance of our fourth quarter and year-end earnings and letter to stockholders yesterday, which we intended to publish immediately after the market close. But as I said earlier, very fortunately, yes, fortunately, after drafting all of our documents and preparing our press release, getting everything ready to go, the most positively consequential thing that has happened to our company actually happened. I mentioned the news that we received from CMS yesterday, which is going to make IHEEZO, which is our low viscosity patented topical anesthetic gel, which is doing fantastic things in clinics and surgery centers across the country.
It’s going to make it separately payable, separately reimbursable in the physician’s office. And it opens up a very large market for IHEEZO and it allows Medicare beneficiaries to experience the unique benefits of the product. So after we calm down from that excitement and we decided to not delay our filings, we made those filings and then ultimately put out a separate Form 8-K before the market opened revealing this wonderful new development. So once again, we apologize for being slightly tardy yesterday in publishing everything I heard from some of our stockholders, but we hope you appreciate that this was an example of no news being very good news. Indeed, yesterday was special for every member of the Harrow family, and it was an answer to some of our prayers actually.
In past letters to stockholders, as I mentioned earlier, I’ve opined about aggregate revenue potential. I said that our product portfolio could achieve $1 billion in annual revenue. If, as I said, some things go our way. Yesterday’s news was an example of a thing that went our way. It’s a beautiful thing for many reasons because we’re seeing amazing stories, practical stories of how IHEEZO is positively changing anesthesia protocols around the country for ophthalmic procedures. It’s even reducing patient exposure to dangerous opioids. Our team feels very good about what we believe is going to happen to IHEEZO and therefore Harrow. So as I close this communication from what has been a world win, couple of days, I want to acknowledge and thank all members of our Harrow family, our loyal employees, their families, who support our employees and our stockholders for their patience and steadfast support.
Your belief in our mission has been a cornerstone of our progress. And together, we’re going to build a company that we can be proud of. Never been truer than today that the very best is not only yet to come for Harrow, but it is soon to come. Thanks to everyone for attending today’s call and for your interest in Harrow. If you have any investor-related questions, please e-mail Jamie Webb at, jwebb@harrowinc.com. This will conclude our call.
Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.
